Eluminex Biosciences Limited announced the completion of over $40 million in Series B financing to advance clinical research on bioengineered corneas based on recombinant collagen proteins and innovative ophthalmic drugs. The company introduced the technology for bioengineered corneas and holds exclusive global licensing rights, making it the first domestic company to synthesize corneas using recombinant collagen proteins.

Eluminex Biosciences utilizes synthetic biology techniques to express full-length type III human collagen proteins with a triple helix structure. One of their products, EB-301, has entered Phase III clinical trials for the treatment of corneal blindness. This technology originated from a research conducted by PER FAGERHOLM and colleagues at Linköping University, Sweden, in 2010, demonstrating that synthetic corneas made from recombinant human collagen proteins can promote corneal tissue and nerve regeneration without the need for immunosuppression. Long-term follow-up has shown durability of over four years, significant improvement in visual acuity, and no corneal melting.

With over 100,000 cases of corneal blindness annually in China, the use of human recombinant type III collagen in bioengineered corneas offers advantages over traditional methods using human donor corneas or pig corneas, which suffer from shortages, limited optical transparency and durability, and immune rejection issues.

Eluminex Biosciences has established a platform for the production of full-length human collagen proteins and has mastered the scalable manufacturing process of recombinant type III human collagen proteins. In addition to bioengineered corneas, recombinant type III human collagen proteins with a triple helix structure hold wide prospects in other fields of tissue regeneration medicine. Eluminex Biosciences stated its continued focus on collagen protein research and development.

Disclaimer: Despite our efforts to maintain accuracy, errors are unavoidable due to our limited expertise. Some information may not be up to date, and we welcome your feedback to make necessary corrections. This document is intended solely for the purpose of providing a business-oriented and written introduction to the field of synthetic biology. It does not constitute any investment advice. We appreciate your understanding.